{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:01Z","timestamp":1794019981361,"version":"4.8.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003725.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T00:00:00Z","timestamp":1462406400000}}],"reference-count":158,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003725.pub4","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T13:57:04Z","timestamp":1462456624000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":210,"title":["Corticosteroids for the treatment of Duchenne muscular dystrophy"],"prefix":"10.1002","volume":"2016","author":[{"given":"Emma","family":"Matthews","sequence":"first","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; Queen Square London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"National Hospital for Neurology and Neurosurgery; MRC Centre for Neuromuscular Diseases; Queen Square London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Kuntzer","sequence":"additional","affiliation":[{"name":"CHU Vaudois and University of Lausanne; Nerve-Muscle Unit, Service of Neurology; Lausanne Switzerland 1011"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Jichi","sequence":"additional","affiliation":[{"name":"Joint Research Office, University College London; UCL School of Life & Medical Sciences; Gower Street London UK WC1E 6BT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan Y","family":"Manzur","sequence":"additional","affiliation":[{"name":"Great Ormond Street Hospital for Children NHS Trust; Dubowitz Neuromuscular Centre; Great Ormond Street London UK WC1N 3JH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,5]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mus.880170405","article-title":"Deflazacort in Duchenne dystrophy: study of long-term effect","volume":"17","author":"Angelini","year":"1994","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0960-8966(94)00048-E","article-title":"Low-dose prednisolone treatment in Duchenne and Becker muscular dystrophy","volume":"5","author":"B\u00e4ckman","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archneur.62.1.128","article-title":"Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial","volume":"62","author":"Beenakker","year":"2005","journal-title":"Archives of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD003725.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0005|cit5","first-page":"A476","article-title":"A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity","volume":"46","author":"Brooke","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0006|cit6","unstructured":"Escolar D McDonald C Kornberg AJ Bertorini T Nevo Y Lotze T Randomized, double-blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy Neurology 2008 A109-10, Abstract no: S05.004"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.0b013e318227b164","article-title":"Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy","volume":"77","author":"Escolar","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Archives of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1001-7","DOI":"10.1002\/mus.24665","article-title":"Daily prednisone treatment in Duchenne muscular dystrophy in southwest China","volume":"52","author":"Hu","year":"2015","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0010|cit10","unstructured":"Karimzadeh P Ghazavi A Comparison of deflazacort and prednisone in Duchenne muscular dystrophy Iranian Journal of Child Neurology 2012 5 12"},{"issue":"24","key":"10.1002\/14651858.CD003725.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0012|cit12","first-page":"38","article-title":"Prednisolone in Duchenne muscular dystrophy","volume":"27","author":"Rahman","year":"2001","journal-title":"Bangladesh Medical Research Council Bulletin"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0013|cit13","unstructured":"Todorovic SM High dose (2 mg\/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy Muscle & Nerve 1998 72"},{"issue":"7-8","key":"10.1002\/14651858.CD003725.pub4-BIB0014|cit14","first-page":"630","article-title":"Low-dosage prednisolone in the long-term treatment of Duchenne muscular dystrophy","volume":"13","author":"Ahlander","year":"2003","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2106\/00004623-200403000-00009","article-title":"Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy","volume":"86-A","author":"Alman","year":"2004","journal-title":"Journal of Bone and Joint Surgery. American Volume"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD003725.pub4-BIB0016|cit16","first-page":"A182","article-title":"Daily versus alternate-day deflazacort (DFZ) in Duchenne muscular dystrophy","volume":"45","author":"Angelini","year":"1995","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mus.20812","article-title":"The role of corticosteroids in muscular dystrophy: a critical appraisal","volume":"36","author":"Angelini","year":"2007","journal-title":"Muscle & Nerve"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0018|cit18","unstructured":"Angelini C Peterle E Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy Acta Myologica 2012 9 15"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0019|cit19","first-page":"187","article-title":"Steroid treatment of Duchenne's muscular dystrophy","volume":"53","author":"Luz Aviles","year":"1982","journal-title":"Revista Chilena de Pediatra"},{"issue":"11","key":"10.1002\/14651858.CD003725.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/01.phm.0000184156.98671.d0","article-title":"Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect","volume":"84","author":"Balaban","year":"2005","journal-title":"American Journal of Physical Medicine and Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","article-title":"Deflazacort treatment of Duchenne muscular dystrophy","volume":"138","author":"Biggar","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"8-9","key":"10.1002\/14651858.CD003725.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.nmd.2004.05.001","article-title":"Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols","volume":"14","author":"Biggar","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromuscular Disorders"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/jnnp.2005.078345","article-title":"The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy","volume":"77","author":"Bonifati","year":"2006","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clinical Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/archneur.1987.00520200016010","article-title":"Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone","volume":"44","author":"Brooke","year":"1987","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Campbell C Jacob P Deflazacort for the treatment of Duchenne Dystrophy: a systematic review BMC Neurology 2003 7","DOI":"10.1186\/1471-2377-3-7"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0960-8966(02)00180-3","article-title":"High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy","volume":"12","author":"Connolly","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1542\/peds.2006-1400","article-title":"Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy","volume":"119","author":"Daftary","year":"2007","journal-title":"Pediatrics"},{"issue":"7-8","key":"10.1002\/14651858.CD003725.pub4-BIB0030|cit30","first-page":"737","article-title":"The effectiveness of prednisolone treatment (10 days on\/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study","volume":"12","author":"Groot","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/archneur.1987.00520200022012","article-title":"Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit","volume":"44","author":"DeSilva","year":"1987","journal-title":"Archives of Neurology"},{"issue":"7894","key":"10.1002\/14651858.CD003725.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"2","author":"Drachman","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/ejpn.2002.0583","article-title":"Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy","volume":"6","author":"Dubowitz","year":"2002","journal-title":"European Journal of Paediatric Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0034|cit34","first-page":"A544","article-title":"Deflazacort treatment and respiratory function in Duchenne muscular dystrophy","volume":"52 Suppl","author":"Dubrovsky","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1991.00530180027012","article-title":"A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy","volume":"48","author":"Fenichel","year":"1991","journal-title":"Archives of Neurology"},{"issue":"12","key":"10.1002\/14651858.CD003725.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/WNL.41.12.1874","article-title":"Long-term benefit from prednisone therapy in Duchenne muscular dystrophy","volume":"41","author":"Fenichel","year":"1991","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1055\/s-0032-1329199","article-title":"The muscular dystrophies","volume":"32","author":"Flanigan","year":"2012","journal-title":"Seminars in Neurology"},{"issue":"3 Pt 1","key":"10.1002\/14651858.CD003725.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.43.3_Part_1.520","article-title":"Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)","volume":"43","author":"Griggs","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Griggs RC Herr BE Reha A Elfring G Atkinson L Cwik V Corticosteroids in Duchenne muscular dystrophy: major variations in practice Muscle & Nerve 2013 27 31","DOI":"10.1002\/mus.23831"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"55-67","DOI":"10.1002\/mus.23808","article-title":"The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures","volume":"48","author":"Henricson","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.pediatrneurol.2007.11.001","article-title":"Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up","volume":"38","author":"Houde","year":"2008","journal-title":"Pediatric Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003725.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/S0960-8966(02)00097-4","article-title":"An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy","volume":"12","author":"Kinali","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2006.12.002","article-title":"Predictive factors for the development of scoliosis in Duchenne muscular dystrophy","volume":"11","author":"Kinali","year":"2007","journal-title":"European Journal of Paediatric Neurology"},{"issue":"19","key":"10.1002\/14651858.CD003725.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily dose corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatric Cardiology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Mayhew AG Cano SJ Scott E Eagle M Bushby K Manzur A Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy Developmental Medicine and Child Neurology 2013 1046 52","DOI":"10.1111\/dmcn.12220"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Mazzone ES Pane M Sormani MP Scalise R Berardinelli A Messina S 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy PloS One 2013 e52512 10.1371\/journal.pone.0052512","DOI":"10.1371\/journal.pone.0052512"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0048|cit48","unstructured":"McAdam LC Mayo AL Alman BA Biggar WD The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy Acta Myologica 2012 16 20"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/mus.10319","article-title":"Early prednisone treatment in Duchenne muscular dystrophy","volume":"27","author":"Merlini","year":"2003","journal-title":"Muscle & Nerve"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-8966(91)90099-E","article-title":"Steroids in Duchenne muscular dystrophy - deflazacort trial","volume":"1","author":"Mesa","year":"1991","journal-title":"Neuromuscular Disorders"},{"issue":"6-7","key":"10.1002\/14651858.CD003725.pub4-BIB0051|cit51","first-page":"630","article-title":"Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years","volume":"11","author":"Pandya","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"2A","key":"10.1002\/14651858.CD003725.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1590\/S0004-282X2007000200011","article-title":"Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy","volume":"65","author":"Parreira","year":"2007","journal-title":"Arquivos de Neuro-Psiquiatria"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00415-006-0212-1","article-title":"Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation","volume":"253","author":"Pradhan","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0387-7604(95)00015-1","article-title":"Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study","volume":"17 Suppl","author":"Reitter","year":"1995","journal-title":"Brain & Development"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0055|cit55","first-page":"630","article-title":"Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series","volume":"11","author":"Resende","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"5-6","key":"10.1002\/14651858.CD003725.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0960-8966(93)90117-3","article-title":"Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule","volume":"3","author":"Sansome","year":"1993","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00131402-200106000-00002","article-title":"Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects","volume":"2","author":"Schara","year":"2001","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Schram G Fournier A Leduc H Dahdah N Therien J Vanasse M All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy Journal of the American College of Cardiology 2013 948 54","DOI":"10.1016\/j.jacc.2012.12.008"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0060|cit60","first-page":"32","article-title":"Failure of corticosteroid in the treatment of Duchenne (pseudo-hypertrophic) muscular dystrophy. Report of a clinically matched three year double-blind study","volume":"145","author":"Siegel","year":"1974","journal-title":"Illinois Medical Journal"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Silva EC Machado DL Resende MB Silva RF Zanoteli E Reed UC Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy Arquivos de Neuro-psiquiatria 2012 191 5","DOI":"10.1186\/1756-0500-5-435"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","article-title":"Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy","volume":"91","author":"Silversides","year":"2003","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Simon VA Resende MB Simon MA Zanoteli E Reed UC Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents Arquivos de Neuro-psiquiatria 2011 19 22","DOI":"10.1590\/S0004-282X2011000100005"},{"issue":"12","key":"10.1002\/14651858.CD003725.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00415-013-7104-y","article-title":"Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients","volume":"260","author":"Takeuchi","year":"2013","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0065|cit65","first-page":"630","article-title":"Alternate day prednisone therapy in Duchenne muscular dystrophy","volume":"11","author":"Tunca","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD003725.pub4-BIB0066|cit66","first-page":"20","article-title":"Duchenne muscular dystrophy: therapeutic options and rehabilitation","volume":"3","author":"Vasanth","year":"1996","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/088307380201700306","article-title":"Corticosteroids in Duchenne muscular dystrophy: a reappraisal","volume":"17","author":"Wong","year":"2002","journal-title":"Journal of Child Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Yilmaz O Karaduman A Aras O Basoglu B Topalo\u011flu H Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis Neuromuscular Disorders 2004 581","DOI":"10.1111\/j.1468-1331.2004.00866.x"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1468-1331.2004.00866.x","article-title":"Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis","volume":"11","author":"Yilmaz","year":"2004","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0070|cit70","unstructured":"ACTRN12605000075684 A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ACTRN12605000075684"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD003725.pub4-BIB0071|cit71","article-title":"Prednisone\/prednisolone and deflazacort differ in long term outcomes on ambulation and side effects in the CINRG Duchenne Natural History Study","volume":"84","author":"Bello","year":"2015","journal-title":"Neurology"},{"issue":"22","key":"10.1002\/14651858.CD003725.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"9","author":"Bello","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ana.24370","article-title":"Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study","volume":"77","author":"Bello","year":"2015","journal-title":"Annals of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"e108205","DOI":"10.1371\/journal.pone.0108205","article-title":"Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes","volume":"9","author":"Pane","year":"2014","journal-title":"PLoS One"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0075|cit75","unstructured":"CTRI\/2009\/091\/000738 A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy http:\/\/apps.who.int\/trialsearch\/Trial2.aspx?TrialID=CTRI\/2009\/091\/000605"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0076|cit76","unstructured":"Guglieri M Van Ruiten HJA Speed C Hart K Watson G McColl E FOR-DMD: Double-blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD) Developmental Medicine and Child Neurology 2015 25 6"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0077|cit77","unstructured":"NCT01603407 Finding the optimum regimen for Duchenne muscular dystrophy (FOR-DMD) www.clinicaltrials.gov\/ct2\/show\/NCT01603407"},{"issue":"7","key":"10.1002\/14651858.CD003725.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1981.00510070040004","article-title":"Loss of strength and functional decline in Duchenne dystrophy","volume":"38","author":"Allsop","year":"1981","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1177\/096368970000900411","article-title":"Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy","volume":"9","author":"Anderson","year":"2000","journal-title":"Cell Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ana.410160206","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells","volume":"16","author":"Arahata","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0081|cit81","volume-title":"Steroid Therapy","author":"Azarnoff","year":"1975"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/jcp.1041020105","article-title":"A synergistic effect of glucocorticosteroids and insulin on the differentiation of myoblasts","volume":"102","author":"Bal","year":"1980","journal-title":"Journal of Cell Physiology"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0960-8966(01)00193-6","article-title":"Reference values of maximum isometric muscle force obtained in 270 children aged 4 -16 years by hand-held dynamometry","volume":"11","author":"Beenakker","year":"2001","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"387-93","DOI":"10.1016\/j.ejpn.2005.06.004","article-title":"Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients","volume":"9","author":"Beenakker","year":"2005","journal-title":"European Journal of Paediatric Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.nmd.2004.09.010","article-title":"Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004","volume":"15","author":"Biggar","year":"2005","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0086|cit86","unstructured":"Joint Formulary Committee British National Formulary (online) www.medicinescomplete.com"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mus.880040304","article-title":"Clinical trial in Duchenne dystrophy. I. The design of the protocol","volume":"4","author":"Brooke","year":"1981","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mus.880060204","article-title":"Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history","volume":"6","author":"Brooke","year":"1983","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0960-8966(02)00213-4","article-title":"107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands","volume":"13","author":"Bushby","year":"2003","journal-title":"Neuromuscular Disorders"},{"issue":"8-9","key":"10.1002\/14651858.CD003725.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.nmd.2004.05.006","article-title":"Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands","volume":"14","author":"Bushby","year":"2004","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.nmd.2007.01.006","article-title":"145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD). 22-24th October 2006, Naarden, The Netherlands","volume":"17","author":"K","year":"2007","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CND.0b013e3181c5053b","article-title":"The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales","volume":"11","author":"Davis","year":"2010","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","article-title":"Pathophysiology of Duchenne muscular dystrophy: Current hypotheses","volume":"36","author":"Deconinck","year":"2007","journal-title":"Pediatric Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0096|cit96","volume-title":"Muscle Disorders in Childhood","author":"Dubowitz","year":"1978"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0960-8966(91)90019-O","article-title":"Prednisone in Duchenne dystrophy","volume":"1","author":"Dubowitz","year":"1991","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0098|cit98","volume-title":"Muscle Disorders in Childhood","author":"Dubowitz","year":"1995"},{"issue":"4-5","key":"10.1002\/14651858.CD003725.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0960-8966(00)00126-7","article-title":"75th European Neuromuscular Centre International workshop: 2nd workshop on the treatment of muscular dystrophy, 10-12 December, 1999, Naarden, The Netherlands","volume":"10","author":"Dubowitz","year":"2000","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S1474-4422(05)70050-8","article-title":"Prednisone for Duchenne muscular dystrophy","volume":"4","author":"Dubowitz","year":"2005","journal-title":"The Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0960-8966(98)00047-9","article-title":"Steroids in muscular dystrophy: Where do we stand?","volume":"8","author":"Dubrovsky","year":"1998","journal-title":"Neuromuscular Disorders"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2353\/ajpath.2006.050683","article-title":"Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative\/nitrosative stresses","volume":"168","author":"Dudley","year":"2006","journal-title":"American Journal of Pathology"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","article-title":"Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation","volume":"12","author":"Eagle","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.nmd.2007.03.002","article-title":"Managing Duchenne muscular dystrophy - the additive effect of spinal surgery and home nocturnal ventilation in improving survival","volume":"17","author":"Eagle","year":"2007","journal-title":"Neuromuscular Disorders"},{"issue":"6261","key":"10.1002\/14651858.CD003725.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/bmj.282.6261.351","article-title":"Clinical usefulness of urinary 3-methylhistidine excretion in indicating muscle protein breakdown","volume":"282","author":"Elia","year":"1981","journal-title":"British Medical Journal (Clinical Research Ed)"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases: a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscular Disorders"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0107|cit107","volume-title":"Diagnostic Criteria for Neuromuscular Disorders","author":"Emery","year":"1997"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0108|cit108","article-title":"Duchenne muscular dystrophy","volume-title":"Oxford Monographs on Medical Genetics","author":"Emery","year":"2003"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.410120314","article-title":"Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers","volume":"12","author":"Engel","year":"1982","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0046-8177(76)80053-6","article-title":"The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis","volume":"7","author":"Frankel","year":"1976","journal-title":"Human Pathology"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199019020-00003","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"19","author":"Frey","year":"1990","journal-title":"Clinical Pharmacokinetics"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/oxfordjournals.bmb.a071623","article-title":"Clinical features and classification of the muscular dystrophies","volume":"36","author":"Gardner-Medwin","year":"1980","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00002060-200206000-00003","article-title":"Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing","volume":"81","author":"Gomez-Merino","year":"2002","journal-title":"American Journal of Physical and Medical Rehabilitation"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1469-8749.1985.tb03763.x","article-title":"Prolongation of walking in Duchenne Muscular Dystrophy with lightweight orthoses; review of 57 cases","volume":"27","author":"Heckmatt","year":"1985","journal-title":"Developmental Medicine and Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/oxfordjournals.bmb.a072358","article-title":"Management of children: pharmacological and physical","volume":"45","author":"Heckmatt","year":"1989","journal-title":"British Medical Bulletin"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0117|cit117","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00002060-199509000-00005","article-title":"A management trial for Duchenne cardiomyopathy","volume":"74","author":"Ishikawa","year":"1995","journal-title":"American Journal of Physical Medicine and Rehabilitation"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0002-8703(99)70414-X","article-title":"Cardioprotection for Duchenne's muscular dystrophy","volume":"137","author":"Ishikawa","year":"1999","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/BF00869001","article-title":"Prednisolone can protect against exercise-induced muscle damage","volume":"243","author":"Jacobs","year":"1996","journal-title":"Journal of Neurology"},{"issue":"10","key":"10.1002\/14651858.CD003725.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0960-8966(03)00162-7","article-title":"The Duchenne muscular dystrophy population in Denmark, 1977-2001: prevalence, incidence and survival in relation to the introduction of ventilator use","volume":"13","author":"Jeppesen","year":"2003","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1212\/WNL.41.5.667","article-title":"Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. CIDD Study Group","volume":"41","author":"Kissel","year":"1991","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0124|cit124","first-page":"498","article-title":"The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion","volume":"45","author":"Koenig","year":"1989","journal-title":"American Journal of Human Genetics"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0960-8966(93)90110-6","article-title":"The role of the dystrophin-glycoprotein complex in the molecular pathogenesis of muscular dystrophies","volume":"3","author":"Matsumura","year":"1993","journal-title":"Neuromuscular Disorders"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/mus.880170103","article-title":"Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies","volume":"17","author":"Matsumura","year":"1994","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1177\/088307389501000219","article-title":"The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability","volume":"10","author":"Mendell","year":"1995","journal-title":"Journal of Child Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"304-13","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD003725.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1111\/j.1476-5381.1995.tb15930.x","article-title":"Modulation by prednisolone of calcium handling in skeletal muscle cells","volume":"116","author":"Metzinger","year":"1995","journal-title":"British Journal of Pharmacology"},{"issue":"7","key":"10.1002\/14651858.CD003725.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"12","key":"10.1002\/14651858.CD003725.pub4-BIB0131|cit131","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010044.pub2","article-title":"Mechanical insufflation-exsufflation for people with neuromuscular disorders","author":"Morrow","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/01.WNL.0000148485.00049.B7","article-title":"Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"64","author":"Moxley","year":"2005","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0133|cit133","volume-title":"Aids to the Investigation of Peripheral Nerve Injuries","author":"Medical Research Council","year":"1976"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003725.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S0960-8966(02)00101-3","article-title":"Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research","volume":"12","author":"Muntoni","year":"2002","journal-title":"Neuromuscular Disorders"},{"issue":"5","key":"10.1002\/14651858.CD003725.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00019052-200310000-00003","article-title":"Cardiomyopathy in muscular dystrophies","volume":"16","author":"Muntoni","year":"2003","journal-title":"Current Opinion in Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"210-9","DOI":"10.1016\/j.nmd.2006.01.004","article-title":"Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK","volume":"16","author":"Muntoni","year":"2006","journal-title":"Neuromuscular Disorders"},{"issue":"6","key":"10.1002\/14651858.CD003725.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/hmg\/ddg065","article-title":"cDNA microarray analysis of individual Duchenne muscular dystrophy patients","volume":"12","author":"Noguchi","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0960-8966(94)00042-8","article-title":"The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells","volume":"5","author":"Pasquini","year":"1995","journal-title":"Neuromuscular Disorders"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjp.0702036","article-title":"Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells","volume":"124","author":"Passaquin","year":"1998","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1096\/fj.06-7285com","article-title":"Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression","volume":"21","author":"Pescatori","year":"2007","journal-title":"The FASEB Journal"},{"issue":"8","key":"10.1002\/14651858.CD003725.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proceedings of the National Academy of Sciences, USA"},{"issue":"1-2","key":"10.1002\/14651858.CD003725.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1023\/A:1006812004945","article-title":"The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy","volume":"179","author":"Petrof","year":"1998","journal-title":"Molecular Cell Biochemistry"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/hmg\/11.3.263","article-title":"A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice","volume":"11","author":"Porter","year":"2002","journal-title":"Human Molecular Genetics"},{"issue":"15","key":"10.1002\/14651858.CD003725.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/hmg\/ddg197","article-title":"Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice","volume":"12","author":"Porter","year":"2003","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.nmd.2004.09.009","article-title":"Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention","volume":"15","author":"Quinlivan","year":"2005","journal-title":"Neuromuscular Disorders"},{"issue":"9","key":"10.1002\/14651858.CD003725.pub4-BIB0146|cit146","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009068.pub2","article-title":"Prevention and treatment for cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy","author":"Quinlivan","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0147|cit147","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0148|cit148","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, & Psychiatry"},{"issue":"1 pt 1","key":"10.1002\/14651858.CD003725.pub4-BIB0149|cit149","first-page":"E67","article-title":"Effect of prednisone on protein metabolism in Duchenne muscular dystrophy","volume":"268","author":"Rifai","year":"1995","journal-title":"American Journal of Physiology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/088307388800300407","article-title":"Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses","volume":"3","author":"Rodillo","year":"1988","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.1002\/14651858.CD003725.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/mus.880050405","article-title":"Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy","volume":"5","author":"Scott","year":"1982","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiotherapy Research International"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.43.3_Part_1.527","article-title":"Cyclosporine increases muscular force generation in Duchenne muscular dystrophy","volume":"43","author":"Sharma","year":"1993","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003725.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2106\/00004623-196244020-00002","article-title":"Bracing for ambulation in childhood progressive muscular dystrophy","volume":"44A","author":"Spencer","year":"1962","journal-title":"Journal of Bone and Joint Surgery"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0304-3940(99)00418-8","article-title":"The effect of methylprednisone on intracellular calcium of normal and dystrophic human skeletal muscle cells","volume":"269","author":"Vandebrouck","year":"1999","journal-title":"Neuroscience Letters"},{"issue":"3","key":"10.1002\/14651858.CD003725.pub4-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub2","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003725.pub4-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub2","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD003725.pub4-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003725.pub2","article-title":"Glucocorticoid corticosteroids for Duchenne muscular dystrophy","author":"Manzur","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003725.pub4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T08:21:51Z","timestamp":1678090911000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003725.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,5]]},"references-count":158,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003725.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,5]]}}}